ArticleFrontiers in pharmacology2022
Folic Acid-Decorated pH-Responsive Nanoniosomes With Enhanced Endocytosis for Breast Cancer Therapy:
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Biotin-mediated drug delivery: does the biotin transporter mediate uptake of biotin conjugates?Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Niosomes as Vesicular Carriers: From Formulation Strategies to Stimuli-Responsive Innovative Modulations for Targeted Drug Delivery.Pharmaceutics · 2025Review
- Niosome-loaded silibinin and methotrexate for synergistic breast cancer combination chemotherapy: in silico and in vitro study.Cancer cell international · 2025Article
- Dual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells.Scientific reports · 2025Article
- Curcumin and Silibinin loaded pegylated nanoniosome for cancer therapy: bioinformatics and in vitro study.Molecular biology reports · 2025Article
- Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
- Smart Drug Delivery Systems Based on Cyclodextrins and Chitosan for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Fabrication of Chrysin-Loaded Hyaluronic Acid Decorated Niosomal Nanoparticles: Potential Anti-inflammatory and Anti-osteoclastic Effects on PBMCs of Rheumatoid Arthritis Patients.Advanced pharmaceutical bulletin · 2025Article
- Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin.Heliyon · 2025Review
- Potential of Natural Phenolic Compounds against Doxorubicin-Induced Chemobrain: Biological and Molecular Mechanisms Involved.Antioxidants (Basel, Switzerland) · 2024Review
- Article
- Efficient targeting of HIF-1α mediated by YC-1 and PX-12 encapsulated niosomes: potential application in colon cancer therapy.Journal of biological engineering · 2023Article
- Therapeutic Candidates for Alzheimer's Disease: Saponins.International journal of molecular sciences · 2023Review
- Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer.Journal of nanobiotechnology · 2023Review
- Multi-responsive chitosan-based hydrogels for controlled release of vincristine.Communications chemistry · 2023Article
- Polyvinyl Alcohol (PVA)-Based Nanoniosome for Enhanced in vitro Delivery and Anticancer Activity of Thymol.International journal of nanomedicine · 2023Article
- Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer.Materials today. Bio · 2022Article
- Niosomes: a novel targeted drug delivery system for cancer.Medical oncology (Northwood, London, England) · 2022Review
- pH-Responsive PEGylated Niosomal Nanoparticles as an Active-Targeting Cyclophosphamide Delivery System for Gastric Cancer Therapy.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common invasive cancer in women and the second leading cause of cancer death in women after lung cancer. The purpose of this study is a targeted delivery toward
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.